These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 20032006

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C, Gulick RM.
    Clin Infect Dis; 2009 Apr 01; 48(7):931-9. PubMed ID: 19231980
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
    Spagnuolo V, Gentilini G, De Bona A, Galli L, Uberti-Foppa C, Soldarini A, Dorigatti F, Seminari E.
    New Microbiol; 2007 Jul 01; 30(3):279-82. PubMed ID: 17802909
    [Abstract] [Full Text] [Related]

  • 52. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
    Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, Antinori S.
    Int J STD AIDS; 2010 Nov 01; 21(11):783-5. PubMed ID: 21187364
    [Abstract] [Full Text] [Related]

  • 53. [CROI 2012: updates on raltegravir].
    MMW Fortschr Med; 2012 May 16; 154 Suppl 1():41. PubMed ID: 22916600
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study.
    Calza L, Danese I, Colangeli V, Vandi G, Manfredi R, Girometti N, Borderi M, Appolloni L, Puggioli C, Viale P.
    AIDS Res Hum Retroviruses; 2014 Dec 16; 30(12):1162-9. PubMed ID: 25369244
    [Abstract] [Full Text] [Related]

  • 57. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
    Hernández-Novoa B, Moreno A, Pérez-Elías MJ, Quereda C, Dronda F, Casado JL, Madrid-Elena N, Aguilar M, Fumero E, Moltó J, Moreno S.
    J Antimicrob Chemother; 2014 Feb 16; 69(2):471-5. PubMed ID: 24097843
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.
    Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L, Franzetti M, Parruti G, Martinelli C, Vichi F, Penco G, Dentone C, Celesia BM, Maggi P, Libertone R, Bagella P, Di Biagio A, Bonfanti P, C.I.S.A.I. Group, Italy.
    Int J Antimicrob Agents; 2015 Mar 16; 45(3):289-94. PubMed ID: 25476452
    [Abstract] [Full Text] [Related]

  • 60. Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
    Ortu F, Weimer LE, Floridia M, Manconi PE.
    Eur J Med Res; 2010 Feb 26; 15(2):81-3. PubMed ID: 20452889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.